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Introduction: Over the past decades, early awareness and alert (EAA) activities and
systems have gained importance and become a key early health technology assessment
(HTA) tool. While a pioneer in HTA, Sweden had no national level EAA activities until 2010.
We describe the evolution and current status of the Swedish EAA System.
Methods: This was a historical analysis based on the knowledge and experience of the
authors supplemented by a targeted review of published and gray literature as well as
documents relating to EAA activities in Sweden. Key milestones and a description of the
current state of the Swedish EAA System is presented.
Results: Initiatives to establish a system for the identification and assessment of
emerging health technologies in Sweden date back to the 1980s. In the 1990s, the
Swedish Agency for HTA and Assessment of Social Services (SBU) supported the
development of EuroScan as one of its founder members. In the mid-2000s, an
independent regional initiative, driven by the Stockholm County Drug and Therapeutics
Committee, resulted in the establishment of a regional horizon scanning function. By
2009, this work had expanded to a collaboration between the four biggest counties in
Sweden. The following year it was further expanded to the national level and since then
the Swedish EAA System has been carrying out identification, filtration and prioritization
of new medicines, early assessment of the prioritized medicines, and dissemination
of information. In 2015, the EAA System was incorporated into the Swedish national
process for managed introduction and follow-up of new medicines. Outputs from the
EAA System are now used to select new medicines for inclusion in this process.
Conclusions: The Swedish EAA System started as a regional initiative and rapidly
grew to become a national level activity. An important feature of the system today is
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its complete integration into the national process for managed introduction and follow-up
of new medicines. The system will continue to evolve as a response both to the changing
landscape of health innovations and to new policy initiatives at the regional, national and
international level.
Keywords: early awareness and alert systems, horizon scanning, health technology assessment, innovation,
health policy, Sweden
INTRODUCTION
The Health Technology Assessment (HTA) Glossary defines
horizon scanning as the systematic identification of health
technologies that are new, emerging or becoming obsolete and
that have the potential to effect health, health services and/or
society (HTA, 2017a). Such systematic identification is typically
carried out as one element within a wider range of related
activities, which is why the term “early awareness and alert
system” has been proposed to capture the extent of the work
immediately following horizon scanning (Packer et al., 2012).
An early awareness and alert (EAA) system is a system that
aims to identify, filter and prioritize new and emerging health
technologies, or new uses of existing interventions; to assess or
predict their impact on health, health services and/or society;
and to disseminate information (HTA, 2017b). The extent of
how information about new and emerging medicines is used
by decision makers can differ, but the consensus is that timely
identification and assessment is generally helpful in supporting
the adoption and use of new health technologies to the benefit of
patients (WHO, 2015).
Over the past two decades, EAA activities and systems
have gained importance and become a key early HTA tool
(Wettermark et al., 2010a; Godman et al., 2015; WHO,
2015). Many of the existing EAA systems are part of the
International Information Network on New and Emerging
Health Technologies (EuroScan International Network) that
currently includes 18 member agencies representing a number
of European countries as well as Australia, New Zealand,
Canada, South Korea and Israel (EuroScan, 2017). There are
also EAA initiatives outside the EuroScan International Network,
such as the Agency for Healthcare Research and Quality
(AHRQ) Healthcare Horizon Scanning System in the United
States (AHRQ, 2017), the Specialist Pharmacy Service (SPS)
in the United Kingdom (NHS, 2017), and the Swedish EAA
System.
While much has been written about the member agencies
of the EuroScan International Network (Simpson et al., 2008;
Packer et al., 2012, 2015), to date there has been no description
of the Swedish EAA System published in the literature, although
its predecessor was mentioned first in an article on a model for
structured introduction of new medicines published in Swedish
(Gustafsson et al., 2008) and then in an article on the forecasting
model developed and used by a regional payer in Sweden
(the Stockholm County Council) (Wettermark et al., 2010b).
This is an important gap as the Swedish EAA System is part
of a comprehensive approach to optimize the introduction of
new medicines (The Swedish Association of Local Authorities
and Regions, 2017a). To address this gap, we documented
the development of the Swedish EAA System and provided a
description of its current status. We believe this will be of interest
to other countries facing similar challenges with the introduction
of new premium priced medicines alongside aging populations
and fixed finite budgets.
METHODS
This overview of the Swedish EAA System is based on the
knowledge and experience of the authors supplemented by a
targeted review of published and gray literature as well as
documents relating to EAA activities in Sweden.
The areas explored in our historical analysis included the
early development of EAA activities in Sweden, the work
of the Swedish Agency for HTA and Assessment of Social
Services (SBU) around early identification and assessment of
new technologies, regional horizon scanning initiatives and
the process of their expansion to the national level as well
as the integration of regional initiatives into the national
process for the structured introduction and follow-up of new
medicines.
In the documentation of the early development of EAA
activities in Sweden and the work of SBU, we mainly relied on
a targeted literature review. Relevant papers on EAA activities
were identified on PubMed using the terms “horizon scanning,”
“early warning system” and “early awareness and alert” combined
with “medicine,” “medication” and “drug.” A manual check of
references for relevant articles was then conducted to identify
further papers. The following websites of the key actors were also
searched: Janusinfo (the website of the Drug and Therapeutic
Committee and the Health and Medical Care Administration of
the Stockholm County Council) (Janusinfo, 2017), the Swedish
Association of Local Authorities and Regions (SALAR) (The
Swedish Association of Local Authorities and Regions, 2017b),
the EuroScan International Network (EuroScan, 2017), and SBU
(The Swedish Agency for HTA and Assessment of Social and
Services, 2017). Finally, additional relevant publications known
to the authors were reviewed.
In the documentation of the regional horizon scanning
initiatives, and the process of their expansion to the national
level, as well as the integration into the national process for
the structured introduction and follow-up of new medicines, we
relied on the knowledge and experience of the authors.
Setting
The key aim of Swedish health policy, similar to that of
other countries with universal healthcare coverage, is to
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provide equitable and comprehensive healthcare for its citizens.
Healthcare in Sweden is primarily funded through direct taxation
(Anell et al., 2012; Anell, 2015). Overall health policy in
Sweden is governed at the national level with, for example, the
Dental and Pharmaceutical Benefits Agency (TLV) maintaining
responsibility related to value-based pricing and reimbursement
of outpatient prescription medicines (Dental and Pharmaceutical
Benefits Agency, 2017). However, decision making is to a large
extent decentralized to county councils responsible for providing
healthcare and medicines to their residents (Anell et al., 2012).
Regional Drug and Therapeutic Committees (DTCs) play an
important role in facilitating rational use of medicines at the
regional level (Godman et al., 2009). All inpatient medicines
are paid for in full by the county councils. For reimbursed
prescriptionmedicines, the county councils receive a government
grant that is negotiated between the national government and
SALAR.
Over the past decade, there has been continuous development
of processes for the structured introduction and follow-up of
new medicines both at the regional and national level. In 2006,
the Stockholm County Council established a regional model for
the introduction and rational use of new medicines (Gustafsson
et al., 2008). As a central part of the National Pharmaceutical
Strategy introduced in 2011, SALAR has led initiatives with
the aim to develop a national collaboration to promote more
effective and safer use of new medicines (Medical Products
Agency, 2017). Today, a national collaboration model is in place
for the managed introduction and follow-up of new medicines
that brings together the county councils, DTCs, governmental
agencies and that also facilitates interaction with pharmaceutical
companies (see Figure 1). Key stakeholders in this model include
the county councils, TLV, and the newly formed New Therapies
(NT) Council that is commissioned to make recommendations
on the use of new medicines with the aim of enabling equal
treatment for patients throughout the country (The Swedish
Association of Local Authorities and Regions, 2017a). The NT
Council is made up of regional representatives with medical
or pharmaceutical expertise. In addition, the NT Council has
members with expertise in other areas such as ethics and health
economics.
RESULTS
We first provide an overview of the evolution of EAA activities in
Sweden, including key milestones, and then describe the current
status of the Swedish EAA System.
Development of EAA Activities in Sweden
Initiatives to establish a system for the identification and
assessment of emerging health technologies in Sweden date back
to the 1980s. In 1984, the Center for Medical Technology
Assessment was established at Linköping University in
collaboration with the local regional payer (i.e., the county
council). A few years later, SBU was established and by the
mid-1990s, a pilot project had been initiated with the objective to
develop and test the feasibility of a model for a national system
for early identification and assessment of new technologies
(Carlsson et al., 1998). This project laid the groundwork for
establishing SBU Alert in 1997. SBU also actively supported the
development of EuroScan and was one of its founder members
(Carlsson et al., 1998; Simpson et al., 2008). SBU however
never assumed a function of identifying new and emerging
health technologies, but rather became an HTA body carrying
out assessments of both new and established technologies
(diagnostics, prevention, treatments) based on proposals coming
from various stakeholders, including clinicians, county councils
and decision making authorities, such as the Medical Products
Agency (MPA) and TLV (Packer et al., 2015). In parallel, the
regional DTCs were tracking new and emerging medicines, thus
providing decision makers with information, albeit not in a
structured and systematic way. Consequently, a structured EAA
system suitable for the needs of the entire healthcare system
(including healthcare payers, clinicians, and other stakeholders)
had to be developed and, by 2007, the Stockholm County Council
had established a horizon scanning function (Gustafsson et al.,
2008).
The creation of this horizon scanning function was driven
by the Stockholm County DTC that, just like other regional
DTCs, had been successful in facilitating rational use of existing
medicines, particularly in general practice (Wettermark et al.,
2008; Godman et al., 2009; Gustafsson et al., 2011; Kardakis et al.,
2015). During the 2000s, the profile of pharmaceutical innovation
however was markedly changing and many more medicines in
the development pipeline were intended for use in specialized
care. It was recognized that a proactive approach with regards
to new specialist medicines was warranted. Uncertainty around
patient outcomes was a key driver in this initiative, however the
growing budget impact of new specialist medicines was also a
contributing factor (Wettermark et al., 2010b). The Stockholm
County Council’s horizon scanning function enabled better
identification and prioritization of new medicines, particularly
new medicines likely to be used in specialized care. This function
was largely influenced by the United Kingdom’s National
Institute for Health Research Horizon Scanning Research and
Intelligence Centre (NIHR HSRIC), which also provided advice
and support in its establishment.
By 2009, the work of the Stockholm County Council’s horizon
scanning function had expanded to a collaboration between the
four biggest county councils in Sweden. This collaboration on
horizon scanning became of interest to other county councils too,
which resulted in expanding the EAA activities to a national level
collaboration facilitated by SALAR. Since 2010, a working group
consisting of staff from the four biggest county councils has been
carrying out EAA activities on behalf of all counties in Sweden.
In 2015, these EAA activities were incorporated into the Swedish
national process for managed introduction and follow-up of new
medicines, which integrated the EAA activities as the first step of
this process.
Description of the Swedish EAA System
In Sweden, the national level EAA activities are referred to as
horizon scanning. In this paper, we will refer to these activities as
the Swedish EAA System, even though this has not been adopted
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FIGURE 1 | The Swedish national process for managed introduction and follow-up of new medicines. Source: The Swedish Association of Local Authorities and
Regions (2017a). Reproduced with permission from Sofie Alverlind.
as its official name, as the scope of the work conducted by the
system is most accurately reflected by this term.
Objective and Scope of the Swedish EAA System
The aim of the Swedish EAA System is to support the long-term
planning of the county councils and to optimize the readiness
of the healthcare system to the introduction of new medicines.
The working group continuously identifies new medicines and
indications expected to be granted marketing authorization
within the next 1–3 years.
Organization and Resources
The Swedish EAA activities are publicly funded. A working
group coordinator leads the work together with a small team
consisting of pharmacists. To gauge the potential impact that
new identified medicines will have on the healthcare system, the
group works closely with the regional DTCs. Affiliated experts
such as clinical pharmacologists and clinicians provide additional
guidance, for example by assessing unmet medical needs and
helping to estimate the value of a new medicine compared
to already existing treatment options. The responsibilities
of the working group include identification, filtration
and prioritization, early assessment, and dissemination of
results.
Customers
The main users of the outputs of the Swedish EAA System are
the county councils (the DTCs and strategic functions) and the
NT Council. The outputs include a horizon scanning database
of identified new and emerging medicines, a list of prioritized
medicines, individual early assessment reports on prioritized
medicines and indications, and quarterly newsletters. Based
on the information from the early assessment reports, the NT
Council makes a decision on whether the medicine should be
included in the national process for managed introduction and
follow-up.
Methods Used in Identification, Filtration, and
Prioritization
Identification
This initial step covers identifying new and emerging medicines
and new therapeutic indications of existing medicines. The
identification process generally spans medicines from phase II–
III of the development until regulatory approval. Medicines
estimated to be of high impact and therefore likely to gain
accelerated assessment with the European Medicines Agency
(EMA), such as certain cancer or orphan medicines, are included
from phase II.
A structured search methodology is employed that includes
a variety of sources that can be classified as primary (e.g., the
manufacturer), secondary (e.g., knowledge or expertise intended
for other purposes) and tertiary (e.g., other EAA systems’
efforts to identify technologies) (Robert et al., 1998). Primary
sources comprise yearly pipeline meetings with individual
pharmaceutical companies. Additional information is obtained
as needed through company contacts and supplemented with
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searches of company websites, including press releases and
investor reports. Secondary sources of information include
regulatory agencies, scientific journals, conference proceedings,
and health technology media outlets. Examples of secondary
sources used include the Swedish MPA, EMA, the United States
Food and Drug Administration, pharmaceutical industry news
sources (e.g., First Word Pharma) and registries of clinical
studies such as ClinicalTrials.gov. Furthermore, a note is taken
of medicines identified by other EAA systems, such as the
NIHR Innovation Observatory and the SPS. The scanning
frequency of these secondary and tertiary data sources vary from
daily to monthly. All identified medicines are entered into a
horizon scanning database that is accessible to all working group
members and representatives from the county councils.
Filtration and prioritization
The filtration and prioritization step involves the evaluation of
which identified medicines may be of importance and impact
treatment of patients or the healthcare system. Medicines with an
expected marketing authorization date in the coming few years
are screened using the following filtration criteria: the patient
population size; burden of disease; budget impact; anticipated
clinical benefits; level of innovation; organizational impact;
impact on treatment guidelines; safety aspects; level of interest
from media and patient organizations; anticipated sub-optimal
market uptake; and relevance from a legal, ethical and/or political
aspect (see the list in Box 1) (The Swedish Association of Local
Authorities and Regions, 2017c). The filtration and prioritization
activities follow a quarterly schedule.
In an initial filtration step, the group identifies medicines that
may have a potential impact on the healthcare system based
on the filtration criteria and summarizes these medicines by
therapeutic area. The results are distributed via the working
group to experts affiliated with the regional DTCs and, if the
necessary expertise is not available through the DTCs, to other
experts for a comment on the new medicine. The experts then
prepare a brief assessment summary. These summaries focus on
the following key aspects: level of innovation; unmet medical
Box 1 | Filtration criteria.
Size of patient population
Severity of the disease
Potential to clinically improve patient outcomes
Innovative way of treating the disease
Potential to affect treatment costs
May require reorganization of the healthcare system
Potential to influence treatment guidelines
Potential safety issues
Potentially high media/public interest
Non-optimal introduction rate following marketing authorization
Potentially legally, ethically, or politically interesting
It is also taken into consideration whether the medicine/indication:
Belongs to a growing class of medicines or therapeutic area
Represents a new form of treatment or a new class of medicines
Is revelant to Swedish conditions
Is in late phase clinical trials (Phase II or Phase III) or is submitted to regulatory
agencies
need; patient population; severity of the disease; potential safety
aspects; media interest; budget impact; and need for changes
to the structure of healthcare delivery should the medicine be
approved for use.
As a second filtration step, the working group meets to
discuss and prioritize (using the same criteria as in the
initial filtration step) the identified medicines based on the
brief assessment summaries. After the meeting, the identified
and prioritized medicines are finally put on a short list and
flagged for subsequent assessment. This list of prioritized
medicines also contains separate sections for completed and
ongoing assessments as well as orphan medicines that have
been submitted to EMA for marketing authorization. The
prioritization list is subsequently shared within the national
collaboration for managed introduction and follow-up of new
medicines. An early assessment report is produced for each
prioritized medicine.
Outputs
The main deliverables of the Swedish EAA System include the
horizon scanning database of identified new medicines, the list
of prioritized medicines, individual early assessment reports
on prioritized medicines and indications, as well as quarterly
newsletters (see Figure 2).
Horizon scanning database of identified new medicines
The horizon scanning database comprising all new and emerging
medicines identified is accessible to all working group members
and is also provided to representatives from the county councils.
Information collected in this database includes the chemical
or code name in the early stages of development as well
as the common/brand name and the Anatomical Therapeutic
Classification (ATC) code. Additional basic information includes
the therapeutic area, indication, mechanism of action and
the manufacturer/developer. Furthermore, the group also
documents development status (including predicted and actual
marketing authorization submission date and EMA filing status),
the predicted marketing authorization date and whether the
identified medicine or indication has an orphan medicine status
designation.
List of prioritized medicines
The updated list of prioritized medicines with information
on the completed, ongoing and planned assessments is also
made available to the customers following the filtration and
prioritization step.
Early assessment report
The work on an early assessment report is initiated following
the manufacturer’s submission of the application for marketing
authorization to EMA. Upon confirmation of filing with the
regulatory authorities, the working group coordinator informs
the working group member tasked to write that specific report.
This working group member then contacts an assigned expert,
most often a clinical pharmacologist or in some cases another
clinician, who initiates the writing process. The four county
councils take turns in writing the reports. Approximately 20 early
assessment reports are produced per year.
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FIGURE 2 | Activities and outputs of the Swedish EAA System.
The completed draft assessment report is shared within
the working group for further input. The three other county
council representatives facilitate an independent expert review
of the assessment report within their respective county. All
comments are then collated and implemented by the working
group coordinator to produce the final early assessment report.
The early assessment report is intended to provide a summary
of the potential value and impact on healthcare delivery that an
upcoming medicine or new indication would bring. The report
follows a structured template and is based on early information
prior to marketing authorization (see Box 2). The important
requirement for the report is that the information used must
come from publicly accessible sources. As such, it does not
provide a formal assessment of a medicine but rather gives
the regional decision makers early information ahead of the
availability of a newmedicine. The report describes themedicine’s
mechanism of action, summarizes what is known about efficacy
and safety from the pivotal trials, and provides an overview
of the therapeutic area, existing treatment guidelines and how
the new medicine would impact healthcare delivery from an
economic and organizational standpoint. In addition, the report
may provide an overview of how the introduction and uptake
of the new medicine can be followed up and assessed in clinical
practice, for example with the use of existing healthcare quality
registries.
The report’s conclusions are not updated when new
information becomes available; however, regulatory information
such as filing and reimbursement status is appended when
available.
Newsletter
The working group publishes a newsletter four times per year
following the filtration and prioritization step. The newsletter is
distributed tomembers of the national collaboration formanaged
introduction and follow-up of new medicines. It reports on
newly identified medicines and indications, recently published
assessment reports, and which medicines were selected for
assessment during the most recent meeting. The newsletter also
contains updates from EMA,MPA, and TLV that are of relevance
from a strategic planning perspective.
Expert Involvement
As mentioned, experts are engaged during the filtration,
prioritization and early assessment steps. The input from these
Box 2 | Components of the early assessment report.
Expert comment/opinion
Description of the medicine
Estimated time to approval
Clinical need and size of patient population
Who will prescribe the medicine
Current treatment alternatives
Clinical efficacy
Clinical observations/safety
Completed and ongoing studies
Other relevant medicines in the pipeline
Estimated cost
Clinical, service, and financial impact
Possibility to monitor utilization post-launch
Other markets
Sales arguments
experts is central in the development of the early assessment
report. The working group members from the four counties are
responsible for putting together the relevant expertise as needed,
primarily relying on experts affiliated with the regional DTCs. All
experts involved in the early assessment of new medicines are
asked to declare any conflicts of interest.
DISCUSSION
In this paper, we provided an overview of the evolution of
the Swedish EAA System from the early discussions in the
1980s to the recent regional work that was expanded to include
other regions and eventually integrated into the national process
for managed introduction and follow-up of new medicines.
Furthermore, we described the current state of the Swedish EAA
System. Such EAA activities and systems have been developed
in many other countries during the last decades (Packer et al.,
2015; WHO, 2015). In their efforts to facilitate rational and
cost-effective use of medicines, healthcare administrators have
broadened their pharmaceutical policy focus from reforms to
promote the use of generics and facilitate the rational use of
existing medicines to the establishment of new models that
improve the introduction of newmedicines (Godman et al., 2015;
Matusewicz et al., 2015).
The Swedish EAA System has a lot in common with
established EAA activities and systems. Its objective and filtration
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and prioritization criteria are similar to that of the EuroScan
International Network members (Packer et al., 2015). The most
obvious differences lie in the type of technology covered, the time
when the identification begins, the customer base and the degree
of integration with other processes.
The Swedish EAA System focuses only on medicines, while
agencies in other countries also cover devices, diagnostics,
interventional procedures and structural changes in healthcare
delivery and organization (Packer et al., 2015). The focus on
medicines may be explained by the track record and knowledge
of both the founding Stockholm County DTC and the DTCs
of the other collaborating counties with a strong base in the
clinic and academia, including experts from pharmacy, clinical
pharmacology and clinicians from different therapeutic areas
(Godman et al., 2009). Furthermore, the considerable impact of
medicines on healthcare budgets (the number two driver of costs
after staff costs) reinforced that medicines became the health
technology covered by the Swedish EAA System (Godman et al.,
2009). It is possible that the focus will change in the future as
the Swedish county councils also are responsible for almost all
other parts of healthcare delivery. Consequently, there is a clear
potential to leverage the work around the introduction of new
medicines to also get a more rational introduction of other health
technologies.
The identification of new medicines starts at various time
points for different agencies (Lepage-Nefkens et al., 2017). For
example, the Italian Horizon Scanning Project issues reports
as early as 36 months prior to expected EMA authorization
(Joppi et al., 2009). The Scottish Medicines Consortium provides
information on all new medicines expected to reach the market
within the next calendar year (Scottish Medicines Consortium,
2015). The Swedish early awareness reports are typically
published 6 months before the authorization of a new medicine.
No evaluation has been made so far on the precision and
appropriateness of the timing. Assessments that are produced too
early may be of limited value for decision makers as they would
be based on scarce published data with many of the evaluated
medicines never reaching the market (Ermisch et al., 2016). On
the other hand, reports published too late may not fulfill the
need for preparatory activities, such as the set-up of registries
to monitor the introduction of a new technology including its
effectiveness and safety in routine clinical practice, the planning
of budgets and the development of quality indicators (Campbell
et al., 2015; WHO, 2015).
Existing EAA systems have a wide variety of customers,
ranging from national governmental health departments
and ministers to hospitals, insurance or reimbursement
organizations, healthcare professionals, medical advisors
and clinical experts (Packer et al., 2015). The Swedish EAA
System has clear ownership by the county councils, which
are responsible for financing healthcare to fulfill the need of
all residents. Consequently, the outputs of the Swedish EAA
System are important for the prioritization of how resources
are used. Furthermore, the EAA System is fully integrated in
other national and regional processes related to the introduction
of new medicines. These include forecasting, priority setting,
pricing and reimbursement, guideline development and
observational studies to monitor the uptake of new medicines
(Gustafsson et al., 2008; Wettermark et al., 2010a,b). It is also
important to acknowledge that the regional ownership facilitates
involvement of clinical experts, which both increases the value of
the assessments and is an important component of the adoption
of new medicines.
There are several challenges that the Swedish EAA System
may face in the future. First, the pharmaceutical area is rapidly
changing with new types of technologies emerging such as cell
and gene therapy medicines. These also have to be taken into
account when prioritizing and estimating the impact of new
health technologies. Second, formedicines that target high unmet
medical need, several schemes exist to facilitate the regulatory
pathway that can lead to new medicines being approved based
on phase II studies. Adaptive pathways for new medicines are
also being proposed (Ermisch et al., 2016). As a result of this, it
can be difficult to foresee when a pharmaceutical company aims
to apply for marketing authorization and if this application will
be based on phase II or phase III studies. Third, the Swedish
national process for managed introduction and follow-up of new
medicines, launched in 2015, is currently being evaluated by
the Swedish Agency for Health and Care Services Analysis. The
scope of the evaluation is to describe the benefit of the process
and to see whether the patients are gaining improved access
to cost-effective medicines. The report is due in 2017 and as a
possible consequence thereof the Swedish EAA System may be
altered.
To summarize, the Swedish EAA System started as a
regional initiative and rapidly grew to become a national level
activity. An important feature of the EAA System today is its
complete integration into the national process for managed
introduction and follow-up of newmedicines as well as the strong
collaboration with experts from the regional DTCs. The EAA
System will continue to evolve as a response both to the changing
landscape of health innovations and to new policy initiatives at
the regional, national and international level.
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